COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
1933 Industries Closes Repurchase and Cancellation of Convertible Debentures
1933 Industries Inc. closes Debenture Repurchase Agreement, repurchasing $475,000 in principal value for $47,500 CAD, removing outstanding liabilities. Agreement conducted in accordance with trust indenture and securities laws -
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. to showcase revolutionary antiviral drug NV-387 at LSX World Congress 2025 in Boston. Update on drug pipeline and platform technologies by Dr. Diwan -
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance -
COMMUNIQUÉ DE PRESSE
Sky Gold Announces Board of Directors and Advisory Board Additions
Sky Gold Corp. welcomes Danae Voormeij and John Duncan to its Board of Directors and Advisory Board, announces resignation of Aaron McBreairty, sets stock options, and focuses on Evening Star gold project in Nevada's Walker Lane trend -
COMMUNIQUÉ DE PRESSE
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences reports positive safety and activity data for Gemini in phase 1b PRIME study for CKD patients, showing reduction in inflammatory activity and cellular response normalization -
-
-
